Edwards Lifesciences (NYSE: EW) exec sells 1,500 common shares
Daveen Chopra, CVP, TMTT & Surgical at Edwards Lifesciences (NYSE: EW), sold 1,500 shares of common stock at a weighted average price of $84.6035 per share. This open-market transaction occurred in multiple trades between $84.6002 and $84.6050. Following the sale, Chopra directly holds 44,324 shares of Edwards Lifesciences, as reported in a Form 4 SEC filing.
Edwards Lifesciences (EW) Form 144: Broker-listed proposed sale notice
Edwards Lifesciences Corporation (EW) has filed a Form 144 notice disclosing a proposed sale of securities through Charles Schwab & Co., Inc. The filing indicates a Performance Stock Lapse of 1,359 shares dated May 7, 2023, and a Restricted Stock Lapse of 141 shares dated May 8, 2023. This is an administrative disclosure for proposed sales and does not confirm actual transactions.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) stock increased by 3.10% to $85.78, outperforming its competitors and the broader market on a strong trading day. The S&P 500 Index rose 0.37% and the Dow Jones Industrial Average gained 0.58%. This marks the third consecutive day of gains for Edwards Lifesciences.
How Investors May Respond To Becton Dickinson (BDX) Loss, Recall And New Interventional Leadership
Becton, Dickinson and Company (BDX) reported a Q2 net loss of US$311 million despite sales of US$4,714 million, while also affirming full-year GAAP revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. The company's investment narrative now focuses on executing in higher growth franchises like BD Interventional and addressing regulatory and quality pressures highlighted by a recent microbiology pouch recall. Despite these challenges, an expanded infection-prevention partnership and solid operational growth initiatives aim to stabilize earnings, though investors are urged to consider the impact of ongoing quality scrutiny on long-term growth.
CONMED Adds Former Johnson & Johnson and Boston Scientific Executives to Board
CONMED Corporation has announced the appointment of Celine Martin and Jeff Mirviss, former executives from Johnson & Johnson and Boston Scientific respectively, to its board of directors. These additions aim to bolster CONMED's strategic oversight and enhance its competitive edge in the MedTech industry, leveraging their extensive experience in surgical technology, global commercialization, and operational leadership. The appointments highlight the evolving governance priorities in MedTech, which increasingly favor operational and commercialization expertise alongside financial oversight.
Medtronic to spend $650M on 60-day nerve therapy for chronic pain
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash. This acquisition will add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, aiming to expand care options for chronic pain sufferers. The deal is expected to close in the first half of Fiscal 2027, subject to regulatory approvals.
North Dakota State Investment Board Buys Shares of 19,728 Edwards Lifesciences Corporation $EW
The North Dakota State Investment Board has acquired a new stake of 19,728 shares in Edwards Lifesciences Corporation, valued at approximately $1.68 million, during the fourth quarter. This move comes as Edwards Lifesciences reported strong quarterly results, exceeding analyst expectations with $0.78 EPS and $1.65 billion in revenue, driven by 16.7% year-over-year revenue growth. Analysts maintain a "Moderate Buy" consensus for the stock with a target price of $95.65, despite recent insider share sales.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of "Hold" from Analysts
Analysts have given Zimmer Biomet Holdings, Inc. (NYSE:ZBH) a consensus "Hold" rating, based on coverage from 23 research firms with an average 12-month price target of $102.80. The company recently exceeded earnings expectations, reporting a 9.3% year-over-year revenue increase and raising its FY2026 EPS guidance. Zimmer Biomet also continues to reward shareholders with a quarterly dividend of $0.24 per share, representing an annual yield of approximately 1.1%.
Gabelli Funds LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Gabelli Funds LLC increased its stake in Zimmer Biomet Holdings, Inc. by 12.4% in the fourth quarter, bringing its total to 130,350 shares valued at $11.7 million. Zimmer Biomet reported stronger-than-expected quarterly results, with $2.09 EPS on revenue of $2.09 billion, up 9.3% year-over-year. While analyst sentiment is mixed with an average "Hold" rating and a price target of $102.80, the company recently announced a quarterly dividend of $0.24 per share.
Shareholders Will Be Pleased With The Quality of Becton Dickinson's (NYSE:BDX) Earnings
Becton Dickinson's recent earnings report, despite a subdued stock price reaction, indicates underlying strength. The company's profits were reduced by US$1.3 billion due to unusual items, which are generally non-recurring, suggesting potential for increased profit in the future if these expenses subside. Becton Dickinson has also shown consistent earnings per share growth of 5.7% annually over the last three years.
Robotics expert Brian Miller on product development, AI and what he learned at Intuitive
Brian Miller, former Intuitive EVP and chief digital officer, shares insights on product development, understanding customer needs, and the role of AI in surgical robotics, drawing from his extensive experience. Now CEO of Sovato, Miller emphasizes the importance of critical thinking, deep customer observation, and responsible use of AI and data in medical device innovation. He also touches on making the most of intraprocedural data and addressing potential "deskilling" concerns with advanced technologies.
The new J&J Shockwave C2 Aero IVL device is faster and more flexible
Johnson & Johnson MedTech has launched its fifth-generation Shockwave Medical C2 Aero coronary intravascular lithotripsy (IVL) catheter, designed for faster and more flexible treatment of complex calcification patterns. The device, which received FDA approval in June 2025, features a redesigned shaft, more flexible balloon material, and a shorter post-pulsing pause time, reducing overall treatment duration by 24%. It also allows for easier repositioning and re-insertion multiple times in the same patient, addressing unmet physician needs for improved deliverability and crossability.
IDEXX Laboratories (Nasdaq:IDXX) - Stock Analysis
This report provides a comprehensive stock analysis of IDEXX Laboratories (IDXX), covering its market performance, financial health, future growth predictions, and recent news. Key highlights include its Q1 2026 revenue growth and increased full-year guidance, driven by strong diagnostics and new product integration like the SDMA kidney biomarker. The analysis also touches on analyst sentiment, insider transactions, and comparisons to competitors.
Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Independent Advisor Alliance
Independent Advisor Alliance significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 85.5% in the fourth quarter. Despite this, Zimmer Biomet reported strong quarterly results, beating analyst estimates for EPS and revenue, and institutional investors collectively own 88.89% of the company's stock. The company also announced a quarterly dividend and analysts currently have a "Hold" rating with an average target price of $102.80.
Handelsbanken Fonder AB Has $102.60 Million Stock Position in Edwards Lifesciences Corporation $EW
Handelsbanken Fonder AB significantly increased its stake in Edwards Lifesciences Corporation by 231.6% in the fourth quarter of 2025, now owning over 1.2 million shares valued at approximately $102.6 million. Edwards Lifesciences (NYSE:EW) recently surpassed quarterly earnings expectations and maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $95.65. Despite positive analyst sentiment, several company insiders have recently sold shares.
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc
Daniel Lippis, CVP, TAVR at Edwards Lifesciences Corp (EW), recently sold 620 shares of the company, bringing his total ownership to 40,410.9103 shares. Over the past year, the company has seen 32 insider sells and no insider buys. Edwards Lifesciences is currently trading at $81.14, and with a GuruFocus Value of $92.21, it is considered modestly undervalued.
Edwards Lifesciences CVP Lippis sells $50,306 of common stock
Daniel J. Lippis, Corporate Vice President at Edwards Lifesciences Corp, sold 620 shares of company stock for $50,306 after exercising employee stock options. This transaction was part of a Rule 10b5-1 trading plan. The article also notes that Edwards Lifesciences, despite a high P/E ratio, appears undervalued according to InvestingPro and recently reported strong Q1 2026 financial results, leading to multiple analyst price target increases.
Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M
Donald E. Bobo Jr., CVP, Strategy/Corp Development at Edwards Lifesciences, sold common stock valued at over $1.4 million on May 15, 2026. The shares were sold at a weighted average price of $82.0732 per share. Following these transactions, Bobo Jr. retained direct ownership of 22,798 shares and indirect ownership of 152,725 shares.
Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading
Edwards Lifesciences executive Daniel J. Lippis exercised employee stock options for 620 shares of common stock at $72.68 per share and subsequently sold those 620 shares on the open market at $81.14 per share. This transaction, executed under a pre-planned Rule 10b5-1 trading plan, is considered routine compensation management. After the sale, Lippis directly holds approximately 40,410.9103 shares of common stock and 6,190 employee stock options.
Edwards Lifesciences (EW) CVP Donald Bobo Jr. sells 17,968 shares in open-market trades
Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences (EW), sold a total of 17,968 common shares in open-market transactions on May 15, 2026. The sales included 8,000 shares indirectly through a 401(k) account at $81.8216 per share and 9,968 shares directly at a weighted average price of $82.0732 per share. Following these transactions, Bobo Jr. holds 22,798.2532 shares directly, 30,969.5756 shares indirectly via a 401(k), and 121,756 shares indirectly in a trust.
Edwards Lifesciences (NYSE: EW) Form 144 lists 150,758 units via broker
Edwards Lifesciences (NYSE: EW) has filed a Form 144 indicating a proposed sale of 150,758 units of common stock through Charles Schwab & Co., Inc. utilizing a "Broker Payment for Cashless Exercise" method. The filing also details four prior sales of common stock by Daniel J. Lippis, a person associated with the company, over the last three months, totaling over 339,000 units. A Form 144 is a statutory notice for affiliates planning to sell a large number of company shares.
Boston Scientific's $1.5B nickel-free heart valve deal with $3B option
Boston Scientific (NYSE: BSX) has announced a $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a company developing proprietary biomaterials. The agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL balloon-expandable TAVR system for an additional $3 billion upon certain clinical and regulatory milestones. This nickel-free heart valve uses a rhenium alloy and is currently undergoing a pivotal trial, with Boston Scientific expecting an immaterial impact on its 2026 earnings per share.
Northwestern Mutual Wealth Management Co. Purchases 1,093,692 Shares of Edwards Lifesciences Corporation $EW
Northwestern Mutual Wealth Management Co. significantly increased its stake in Edwards Lifesciences Corporation by 1,952.7%, acquiring an additional 1,093,692 shares, bringing its total holdings to 1,149,700 shares valued at approximately $98.0 million. The medical research company recently reported strong earnings, beating analyst expectations with 16.7% year-over-year revenue growth. Despite this positive financial performance and largely favorable analyst ratings, Edwards Lifesciences has seen notable insider selling, with a CFO and VP selling a combined 88,096 shares in the last 90 days.
INVO Bioscience stock (US44984F1049): merger story, Nasdaq relisting and fertility-tech ambitions
INVO Bioscience is undergoing a transformation in fertility technology, driven by a planned merger with NAYA Biosciences and a reverse stock split that facilitated its relisting on Nasdaq. The company focuses on its INVOcell device for in-vivo incubation, aiming to provide a lower-cost alternative to conventional IVF, targeting fertility clinics and patients seeking assisted reproduction. For investors, INVO Bioscience represents a speculative opportunity in the growing fertility-tech market, though it carries risks associated with its small market capitalization and ongoing losses.
Intuitive Surgical, Inc. (NASDAQ:ISRG) Given Consensus Rating of "Moderate Buy" by Brokerages
Intuitive Surgical (NASDAQ:ISRG) has received a consensus "Moderate Buy" rating from twenty-six brokerages, with an average 12-month price target of $581.91. This comes after the medical equipment provider topped earnings expectations, reporting EPS of $2.50 and revenue of $2.77 billion. Despite recent insider selling and the stock trading near its 52-week low, institutional ownership remains high at over 83%.
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment
Abbott Laboratories (ABT) is under scrutiny due to sales declines in its Nutrition business, legal uncertainties, and cautious analyst sentiment, despite product launches and recovering volumes. While the stock has seen a significant pullback over the last year, Simply Wall St's narrative suggests it is 25.8% undervalued with a fair value of $113.88, viewing it as a long-duration growth story. However, this valuation depends on the easing of Nutrition headwinds and the successful integration of Exact Sciences without further pressure from legal issues.
[144] Edwards Lifesciences Corp SEC Filing
Edwards Lifesciences (EW) filed a Form 144 disclosing proposed insider sales by Donald E. Bobo Jr. The filing details multiple equity compensation-based disposals, including proposed sales on February 25, 2026, March 2, 2026, and April 2, 2026, with specified share quantities and aggregate dollar amounts. The securities involved are identified as RSU/PSU, highlighting the nature of the compensation.
CapsoVision (Nasdaq:CV) - Stock Analysis
CapsoVision (Nasdaq:CV) is a medical technology company specializing in endoscopic video imaging devices for gastrointestinal imaging, currently valued at US$322.5m. The company faces significant financial risks, including less than a year of cash runway and continued unprofitability, although revenue is forecast to grow by 27.2% annually. Recent developments include an FDA 510(k) submission for an AI-assisted reading module and a Breakthrough Device Designation application for pancreatic cancer screening.
Why LeMaitre Vascular (LMAT) Is Down 10.9% After Raising 2026 Guidance And Boosting Dividends
LeMaitre Vascular (LMAT) experienced a 10.9% stock decline despite reporting stronger Q1 sales and net income, raising its full-year 2026 guidance, and increasing its quarterly dividend. The company's updated outlook highlights management's confidence but also brings focus to risks around the sustainability of price increases and product concentration. Investors are encouraged to assess whether margin expansions, partly due to pricing, can be maintained in the long term.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) shares rose 2.08% to $81.39 on Wednesday, outperforming the S&P 500 Index which gained 0.58% and the Dow Jones Industrial Average which fell 0.14%. This marks the stock's second consecutive day of gains despite a mixed trading session for the broader market.
[Form 4] Edwards Lifesciences Corp Insider Trading Activity
This article details an insider trading activity for Edwards Lifesciences Corp (EW) as reported in a Form 4 filing. CEO Bernard J. Zovighian was identified as a net seller, disposing of 36,351 shares worth $2.83 million through several transactions. These transactions were executed under a Rule 10b5-1 trading plan and involved the exercise of performance rights and subsequent sales of common stock.
Edwards Lifesciences CEO Zovighian sells $2.83m in shares
Bernard J. Zovighian, CEO of Edwards Lifesciences Corp, sold 36,351 shares of the company's common stock worth approximately $2.83 million on May 12, 2026. This sale occurred shortly after he acquired 47,207 shares from the vesting of performance-based restricted stock units. Despite the insider sale and downward revision of earnings expectations by some analysts, the company reported strong Q1 2026 financial results with significant revenue and EPS growth, leading several analysts to reiterate Buy ratings.
[Form 4] Edwards Lifesciences Corp Insider Trading Activity
This article reports on insider trading activity at Edwards Lifesciences Corp (EW) based on a Form 4 filing. Daveen Chopra, CVP, TMTT & Surgical, exercised performance rights for 13,583 shares and had 7,538 shares withheld for tax purposes at a price of $79.96, reducing their common stock holdings. The filing details the vesting of restricted stock units granted in 2023.
Edwards Lifesciences (NYSE: EW) lists vested RSUs and prior 22,430-share sale
Edwards Lifesciences Corporation submitted a Form 144 notice disclosing proposed sales related to recent equity-compensation vesting events. The filing detailed restricted stock lapses occurring on May 3, 2026, May 7, 2026, and May 8, 2026, totaling over 10,000 shares, as well as a PSU/RSU entry for 26,640 shares on May 11, 2026. Additionally, the report noted a prior sale of 22,430 shares for $1,719,742.00 on February 12, 2026, by Bernard J Zovighian.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) saw its stock rally 3.32% to $79.73 on Tuesday, outperforming the mixed market session. This rise ended a three-day losing streak for the company. The Dow Jones Industrial Average closed up 0.11%, while the S&P 500 Index fell 0.16%.
Home Depot vs. Lowe’s: One Dividend Has Room to Double
This article compares Home Depot (HD) and Lowe's (LOW) based on their Q4 fiscal 2025 earnings and dividend sustainability. Home Depot showcased a stronger balance sheet and better comparable sales, suggesting its dividend has more room for growth, even with tightening free cash flow coverage. In contrast, Lowe's missed earning estimates and is facing negative shareholders' equity, indicating its dividend is maintained through less sustainable methods like favorable timing and heavy acquisition debt.
The Bull Case For Becton Dickinson (BDX) Could Change Following CFO Shift And EPS Upgrade – Learn Why
Becton Dickinson (BDX) recently appointed Vitor Roque as CFO and raised its full-year adjusted EPS guidance after exceeding Q2 expectations. This leadership change and improved outlook, alongside product launches like the BD CentroVena One Insertion System, are critical for the company's "New BD" strategy to convert its broad medtech portfolio into more stable earnings. While the raised guidance offers a short-term catalyst, investors should be mindful of ongoing margin pressures and divergent analyst views on long-term risks.
Earnings To Watch: STAAR Surgical (STAA) Reports Q1 Results Tomorrow
STAAR Surgical (STAA) is set to report its Q1 results this Wednesday, with the market expecting an 81.8% year-on-year revenue growth. This comes after the company missed analysts' revenue and EPS estimates last quarter. Analysts have grown more bearish recently, although the medical devices & supplies - specialty segment has seen positive investor sentiment.
Edwards Lifesciences CVP Wayne Markowitz sells $47,279 in stock
Wayne Markowitz, Corporate Vice President at Edwards Lifesciences, sold 593 shares of company stock for $47,279 on May 11, 2026, following other dispositions for tax obligations. Despite the stock sale, Markowitz also received significant grants of restricted stock units, employee stock options, and performance rights. This news comes as Edwards Lifesciences reported strong Q1 2026 results and announced a new CFO, maintaining positive analyst ratings.
Edwards Lifesciences (NYSE: EW) executive logs routine tax-withholding share disposition
An executive at Edwards Lifesciences (NYSE: EW), Daniel J. Lippis, reported a routine tax-withholding disposition of 362 common shares on May 11, 2026. These shares, valued at $79.96 each, were disposed of to cover tax obligations rather than being sold on the open market. Following this transaction, Lippis directly holds approximately 40,410.91 shares.
Edwards Lifesciences (EW) CEO awarded stock, options and makes share gifts
Edwards Lifesciences CEO Bernard J. Zovighian received significant equity compensation, including restricted stock units, performance-based stock units, and stock options, as detailed in a recent Form 4 filing. These grants are part of the company's Long-Term Stock Incentive Compensation Program and are subject to various vesting schedules. Additionally, Zovighian reported bona fide share gifts and tax-withholding dispositions, outlining his current direct and indirect stock holdings in the company.
Edwards Lifesciences (NYSE: EW) CVP logs sale and major equity awards
Edwards Lifesciences CVP, JAPAC, Wayne Markowitz, reported an open-market sale of 593 shares of common stock at $79.73 per share on May 11, 2026. Prior to this sale, on May 7, 2026, he received 5,200 restricted stock units, 5,200 performance-based restricted stock units, and 26,400 employee stock options. Additionally, 490 shares were disposed of between May 7 and May 8 for tax-withholding purposes related to equity compensation.
Edwards Lifesciences CVP Wayne Markowitz sells $47,279 in stock
Wayne Markowitz, CVP at Edwards Lifesciences, sold 593 shares worth $47,279 on May 11, 2026. This follows earlier sales for tax obligations and comes as the stock trades near its 52-week low. The company recently reported strong Q1 2026 results and appointed a new CFO.
Edwards Lifesciences (NYSE: EW) CFO exercises performance units, withholds 11,004 shares for taxes
Edwards Lifesciences CFO Scott B. Ullem exercised 19,830 Performance Rights into common shares after 167.70% of his target units vested. To cover tax obligations, 11,004 shares were withheld at $79.96 per share. After these transactions, Ullem directly holds 46,740 common shares and indirectly holds 266,318 shares through a trust.
Is Edwards Lifesciences Corp (EW) a Bargain After 3.5% Drop? GF Value Says Undervalued
Edwards Lifesciences Corp (EW) recently experienced a 3.5% stock drop, yet GuruFocus's GF Value suggests it is 16.3% undervalued, with a GF Score of 97/100 indicating strong fundamentals. Despite its current P/E ratio being higher than its historical median, the potential undervaluation, especially in growth and valuation scores, presents a favorable opportunity for investors. However, significant insider selling activity, totaling $9.0 million in the last three months with no buying, warrants a cautious approach.
[144] Edwards Lifesciences Corp SEC Filing
Edwards Lifesciences Corporation has submitted a Rule 144 notice, disclosing proposed transactions in common stock and restricted stock lapse events. The filing specifies sales quantities of 47,280.00 and 575,800,000, along with lapses of 19 shares on May 7, 2025, and 574 shares on May 7, 2026. This SEC filing provides transparency regarding the impending release of restricted stock into the market, which could influence the company's share price.
IDEXX Laboratories Drops 5.8% Amid Sector-Wide Selling
IDEXX Laboratories experienced a 5.8% drop on Monday, with its stock falling to $527.42 amidst a broad selloff affecting the healthcare technology sector. This decline, which saw its market capitalization reduced to $41.6 billion, occurred without any clear company-specific news, regulatory announcements, or analyst downgrades. The coordinated downturn suggests broader sector-wide pressures, possibly due to institutional repositioning or concerns over valuation multiples, rather than issues specific to IDEXX.
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors
Edwards Lifesciences Corp. (EW) stock decreased by 3.49% on Monday, closing at $77.17. This underperformance occurred despite a generally positive trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average rising by 0.19%. This marks the third consecutive day of losses for Edwards Lifesciences Corp. stock.
TTM Shares Surge 68% as Revenue Outlook Accelerates
TTM Technologies Inc. has seen its shares surge by nearly 70% in the past month, adding about $7 billion in market value and moving its ranking to the fourth most valuable public company headquartered in Orange County. CEO Edwin Roks attributes this growth to "megatrends" in data centers, networking, aerospace, and defense, with the company projecting $4 billion in sales for the current year. TTM plans to discuss its business and future opportunities at its 2026 Investor Day on May 27th, and is also considering a headquarters move from Santa Ana to Irvine.
Intuitive Surgical Drops 6.3% Amid Sector-Wide Selling
Intuitive Surgical's stock dropped 6.3% on Monday to $421.86, caught in a broad wave of selling across the medical technology sector. Despite no company-specific negative news, the robotic surgery leader experienced a significant decline, alongside peers like Edwards Lifesciences and IDEXX Laboratories, suggesting a macro or sentiment-driven market shift. The disproportionate fall raises questions about its premium valuation or higher volatility in a declining market.
